New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
10:03 EDTATR, TEN, SFUN, MRVL, MRO, IPSEY, FNSR, CSH, CCG, BLL, LULUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AptarGroup (ATR) downgraded to Underperform from Neutral at BofA/Merrill... Ball Corp. (BLL) downgraded to Neutral from Buy at BofA/Merrill... Campus Crest (CCG) downgraded to Underperform from Neutral at BofA/Merrill... Cash America (CSH) downgraded to Market Perform at FBR Capital... Finisar (FNSR) downgraded to Hold from Buy at Craig-Hallum... Ipsen (IPSEY) downgraded to Neutral from Overweight at JPMorgan... Marathon Oil (MRO) downgraded to Market Perform from Outperform at Wells Fargo... Marvell (MRVL) downgraded at Susquehanna... Rackspace (RAX) downgraded to Underperform from Neutral at DA Davidson... SouFun (SFUN) downgraded to Neutral from Overweight at JPMorgan... Tenneco (TEN) downgraded to Hold from Buy at Deutsche Bank... lululemon (LULU) downgraded to Neutral from Overweight at JPMorgan.
News For ATR;BLL;CCG;CSH;FNSR;IPSEY;MRO;MRVL;SFUN;TEN;LULU From The Last 14 Days
Check below for free stories on ATR;BLL;CCG;CSH;FNSR;IPSEY;MRO;MRVL;SFUN;TEN;LULU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
06:03 EDTCSHCash America sees FY14 EPS $4.20-$4.40, consensus $4.30
Subscribe for More Information
06:03 EDTCSHCash America sees Q3 EPS 70c-80c, consensus 81c
Subscribe for More Information
06:01 EDTCSHCash America reports Q2 non-GAAP EPS $1.04, consensus 88c
Reports Q2 revenue $455.09M, consensus $433.29M
July 23, 2014
16:54 EDTCSHCash America CEO Daniel Feehan to retire in April 2015
Subscribe for More Information
July 22, 2014
09:52 EDTSFUNSouFun spikes higher on heavy volume, levels to watch
Subscribe for More Information
July 21, 2014
17:09 EDTATRAptarGroup sees Q3 EPS 72c-77c, consensus 77c
Subscribe for More Information
17:05 EDTATRAptarGroup reports Q2 EPS 79c, consensus 82c
Reports Q2 revenue $670.63M, consensus $683.56M. Beauty and home product sales increased 3%, Pharma product sales increased 4%, food and beverage sales increased 7%. Total Q2 sales increased 4% excluding currency effects.
06:45 EDTLULUlululemon files lawsuit against 'knockoff artists', The Globe and Mail says
Subscribe for More Information
July 18, 2014
06:06 EDTLULUStocks with implied volatility below IV index mean; LULU INTC
Subscribe for More Information
July 17, 2014
10:07 EDTLULULululemon Athletica July calls active on renewed takeover chatter
Subscribe for More Information
09:53 EDTLULURumor: lululemon moves up on renewed takeover chatter
09:37 EDTCSHCash America proposed UK rate caps will reduce profits, FBR Capital
Subscribe for More Information
05:56 EDTLULUStocks with implied volatility below IV index mean; LULU INTC
Subscribe for More Information
05:21 EDTIPSEYIpsen Somatuline CLARINET Phase III results published in NEJM
Ipsen announced that the New England Journal of Medicine, or NEJM, has published clinical trial results showing that Somatuline Autogel/Somatuline Depot Injection 120 mg achieved statistically significant prolongation of progression free survival over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. CLARINET, an investigational phase III randomized, double-blind, placebo-controlled study of the antiproliferative effects of Somatuline was conducted in 48 centers across 14 countries. The article titled “Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors” has been published in the July 17 edition. The data gathered from 204 GEP-NET patients over the 96-week study showed that placebo-treated patients had a median PFS of 18.0 months and 33.0% had not progressed or died at 96 weeks, whereas the median PFS for Somatuline treated patients was not reached and 65.1% had not progressed or died at 96 weeks. This represented a 53% reduction in risk of disease progression or death based on a hazard ratio of 0.47. These statistically and clinically significant antiproliferative effects of Somatuline were observed in a large population of patients with grade G1 or G2 GEP-NETs, and independent of hepatic tumor volume. Quality of life measures were not different between the Somatuline and placebo groups. Safety data generated from the study are consistent with the known safety profile of Somatuline.
July 16, 2014
10:00 EDTCSHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:53 EDTCSHCash America upgraded at Sterne Agee
Subscribe for More Information
07:05 EDTCSHCash America upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
05:51 EDTLULUStocks with implied volatility below IV index mean; LULU LL
Subscribe for More Information
July 15, 2014
07:17 EDTATRFarnborough International to hold air show
Subscribe for More Information
06:03 EDTLULUStocks with implied volatility below IV index mean; LULU LL
Stocks with implied volatility below IV index mean; lululemon (LULU) 36, Lumber Liquidators (LL) 53 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use